Adjusting overall survival for treatment switches: commonly used methods and practical application-Reference-Cited by-同舟云学术

Adjusting overall survival for treatment switches: commonly used methods and practical application

Published:2013-10-18 Issue:6 Volume:12 Page:348-357
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Watkins Claire¹,Huang Xin²,Latimer Nicholas³,Tang Yiyun²,Wright Elaine J.⁴

Affiliation:

1. AstraZeneca; Macclesfield, Cheshire UK

2. Pfizer; La Jolla CA USA

3. University of Sheffield; Sheffield South Yorkshire UK

4. Roche; Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1602/fullpdf

Reference25 articles.

1. Correcting for noncompliance in randomized trials using rank preserving structural failure time models;Robins;Communications in Statistics-Theory and Methods,1991

2. Robins J Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate markers Proceedings of the Biopharmaceutical Section, American Statistical Association 1993 24 33

3. Statistical principles for clinical trials: ICH harmonized tripartite guideline;ICH E9 Expert Working Group;Statistics in Medicine,1999

4. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study;Morden;BMC Medical Research Methodology,2011

5. G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients;Robins;Epidemiology,1992

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses;JCO Precision Oncology;2024-04

2. Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials;BMJ Oncology;2024-04

3. A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study;BMC Medical Research Methodology;2024-01-22

4. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer;Future Oncology;2024-01-17

5. Adjusting for Time-Varying Treatment Switches in Randomized Clinical Trials: The Danger of Extrapolation and How to Address It;Statistics in Biopharmaceutical Research;2023-11-29